485 ROUTE 1 SOUTH, ISELIN, NJ
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Registered Direct Offering of 8,539,709 Shares by Outlook Therapeutics
Registered Direct Offering - Outlook Therapeutics to Sell 8.54M Shares
Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
At The Market Offering Agreement with H.C. Wainwright for $100M
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report